113 related articles for article (PubMed ID: 7934136)
1. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes.
Yokose N; Ogata K; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T
Leuk Res; 1994 Oct; 18(10):777-82. PubMed ID: 7934136
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
Ogata K; Yokose N; Nomura T
Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
[TBL] [Abstract][Full Text] [Related]
3. Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF.
Zwierzina H; Herold M; Schöllenberger S; Geissler D; Schmalzl F
Br J Haematol; 1991 Nov; 79(3):438-43. PubMed ID: 1751371
[TBL] [Abstract][Full Text] [Related]
4. Plasma soluble interleukin-2 receptors in patients with myelodysplastic syndromes.
Yokose N; Ogata K
Leuk Lymphoma; 1997 Dec; 28(1-2):171-6. PubMed ID: 9498716
[TBL] [Abstract][Full Text] [Related]
5. Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome.
Ogata K; Yokose N; An E; Kamikubo K; Tamura H; Dan K; Sakamaki H; Onozawa Y; Hamaguchi H; Nomura T
Br J Haematol; 1996 Apr; 93(1):45-52. PubMed ID: 8611474
[TBL] [Abstract][Full Text] [Related]
6. Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes.
Ogata K; Yokose N; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T
Br J Haematol; 1994 Mar; 86(3):562-7. PubMed ID: 8043438
[TBL] [Abstract][Full Text] [Related]
7. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome.
Pülhorn H; Herrmann M; Harms H; Jung A; Baumann I
Histopathology; 2012 Aug; 61(2):200-11. PubMed ID: 22690734
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
[TBL] [Abstract][Full Text] [Related]
10. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
Paietta E; Nelson DL; Andersen J; Dutcher JP; Wiernik PH
Med Oncol; 1995 Jun; 12(2):121-4. PubMed ID: 8535662
[TBL] [Abstract][Full Text] [Related]
11. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome.
Iwase O; Aizawa S; Kuriyama Y; Yaguchi M; Nakano M; Toyama K
Ann Hematol; 1995 Dec; 71(6):293-9. PubMed ID: 8534761
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome.
Hamdi W; Ogawara H; Handa H; Tsukamoto N; Murakami H
Int J Lab Hematol; 2009 Dec; 31(6):630-8. PubMed ID: 18691343
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
14. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
15. [Effect of shenmai injection on sIL-2R NK and LAK cells in patients with advanced carcinoma].
Feng PF; Liu LM; Shen YY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1995 Feb; 15(2):87-9. PubMed ID: 7787398
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of regulatory T cells in patients with myelodysplastic syndrome.
Hamdi W; Ogawara H; Handa H; Tsukamoto N; Nojima Y; Murakami H
Eur J Haematol; 2009 Mar; 82(3):201-7. PubMed ID: 19018862
[TBL] [Abstract][Full Text] [Related]
17. Analysis of leucocyte differentiation antigens in blood and bone marrow in patients with refractory anaemia (RA) and RA with sideroblasts. Prognostic implications of sequential and follow-up data.
Kerndrup G; Bendix-Hansen K; Pedersen B; Ellegaard J; Hokland P
Eur J Haematol; 1988 Oct; 41(4):368-74. PubMed ID: 3197823
[TBL] [Abstract][Full Text] [Related]
18. Increased serum interleukin 6 levels in patients with myelodysplastic syndromes.
Herold M; Schmalzl F; Zwierzina H
Leuk Res; 1992; 16(6-7):585-8. PubMed ID: 1635376
[TBL] [Abstract][Full Text] [Related]
19. Expression of interleukin-2 receptor by activated peripheral blood lymphocytes upregulated by the plasma level of interleukin-2 in patients with recurrent aphthous ulcers.
Sun A; Chu CT; Liu BY; Wang JT; Leu JS; Chiang CP
Proc Natl Sci Counc Repub China B; 2000 Jul; 24(3):116-22. PubMed ID: 10943944
[TBL] [Abstract][Full Text] [Related]
20. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
